Zylox-Tonbridge Medical Technology Co., Ltd. Class H (HK:2190)
:2190
Want to see HK:2190 full AI Analyst Report?
2190 Stock Chart & Stats
HK$24.64
HK$0.06(0.55%)
At close: 4:00 PM EST
HK$24.64
HK$0.06(0.55%)
Day’s Range― - ―
52-Week RangeHK$18.00 - HK$28.00
Previous CloseN/A
Volume305.57K
Average Volume (3M)743.29K
Market Cap
HK$6.58B
Enterprise ValueHK$4.86B
Total Cash (Recent Filing)HK$1.73B
Total Debt (Recent Filing)HK$63.67M
Price to Earnings (P/E)21.8
Beta0.67
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.48%
Share Statistics
EPS (TTM)0.76
Shares Outstanding336,350,740
10 Day Avg. Volume433,268
30 Day Avg. Volume743,287
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)2.08
Price to Sales (P/S)6.35
P/FCF Ratio24.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$30.22Price Target Upside22.63% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.99
Revenue Forecast (FY)HK$1.49B
Bulls Say, Bears Say
Bulls Say
Financial PerformanceAdjusted net income surged by 68.1% year over year to Rmb131mn, reaching an adjusted net margin of 27.3%.
Global ExpansionZylox is actively establishing a localized commercial team globally, and as overseas sales scale expands, gross profit margin is expected to be similar to that of the China business level.
Market OpportunitiesVBP guidelines are becoming more lenient, allowing new entrants to participate at the average bidding price from the last round, which should benefit quality new domestic entrants like Zylox.
Bears Say
Expansion RisksManagement targets overseas sales to account for approximately 20-30% of the total by 2027, seeking to expedite expansion via mergers and acquisitions with a target sales scale of Rmb100mn+.
Investment RisksThe risk-reward update suggests favorable conditions for investment in Zylox-Tonbridge Medical Technology Co.
Market CompetitionProjected sales and net profit growth are strong, aligning with management guidance.
Zylox-Tonbridge Medical Technology Co., Ltd. Class H News
2190 FAQ
What was Zylox-Tonbridge Medical Technology Co., Ltd. Class H’s price range in the past 12 months?
Zylox-Tonbridge Medical Technology Co., Ltd. Class H lowest stock price was HK$18.00 and its highest was HK$28.00 in the past 12 months.
What is Zylox-Tonbridge Medical Technology Co., Ltd. Class H’s market cap?
Zylox-Tonbridge Medical Technology Co., Ltd. Class H’s market cap is HK$6.58B.
When is Zylox-Tonbridge Medical Technology Co., Ltd. Class H’s upcoming earnings report date?
Zylox-Tonbridge Medical Technology Co., Ltd. Class H’s upcoming earnings report date is Aug 31, 2026 which is in 78 days.
How were Zylox-Tonbridge Medical Technology Co., Ltd. Class H’s earnings last quarter?
Zylox-Tonbridge Medical Technology Co., Ltd. Class H released its earnings results on Mar 17, 2026. The company reported HK$0.422 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.422.
Is Zylox-Tonbridge Medical Technology Co., Ltd. Class H overvalued?
According to Wall Street analysts Zylox-Tonbridge Medical Technology Co., Ltd. Class H’s price is currently Undervalued.
Does Zylox-Tonbridge Medical Technology Co., Ltd. Class H pay dividends?
Zylox-Tonbridge Medical Technology Co., Ltd. Class H pays a Notavailable dividend of HK$0.252 which represents an annual dividend yield of 0.48%. See more information on Zylox-Tonbridge Medical Technology Co., Ltd. Class H dividends here
What is Zylox-Tonbridge Medical Technology Co., Ltd. Class H’s EPS estimate?
Zylox-Tonbridge Medical Technology Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Zylox-Tonbridge Medical Technology Co., Ltd. Class H have?
Zylox-Tonbridge Medical Technology Co., Ltd. Class H has 336,350,740 shares outstanding.
What happened to Zylox-Tonbridge Medical Technology Co., Ltd. Class H’s price movement after its last earnings report?
Zylox-Tonbridge Medical Technology Co., Ltd. Class H reported an EPS of HK$0.422 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.696%.
Which hedge fund is a major shareholder of Zylox-Tonbridge Medical Technology Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2190
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Zylox-Tonbridge Medical Technology Co., Ltd. Class H
Zylox-Tonbridge Medical Technology Co., Ltd. is a global medical device firm specializing in neurovascular and peripheral vascular interventional technologies. Their comprehensive product line for treating ischemic stroke includes the ThromBite Clot Retriever, designed to extract clots from major brain vessels, as well as aspiration and balloon guiding catheters. For peripheral vascular conditions, they offer the ZENFLEX Pro Drug-eluting Stent System for managing complex and recurring symptomatic lesions, the self-expanding ZENFlex Peripheral Stent System for deployment in the iliac, superficial femoral, and proximal popliteal arteries, and drug-coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheters for treating arterial stenoses or blockages in these same regions. Their neurovascular offerings further extend to Ton-Bridge extra soft coils, utilized for the endovascular embolization of intracranial aneurysms and other cerebral vascular malformations like arteriovenous malformations (AVMs) and fistulae. Supporting these are a range of microcatheters (for coiling or selective agent delivery), distal access and intracranial PTA balloon catheters, vascular snares, and IVC filter snare retrieval kits. Established in 2012, Zylox-Tonbridge Medical Technology Co., Ltd. maintains its headquarters in Zhejiang, People's Republic of China.
Zylox-Tonbridge Medical Technology Co., Ltd. Class H (2190) Earnings & Revenues
2190 Stock 12 Month Forecast
Average Price Target
HK$30.22
▲(22.63% Upside)
Technical Analysis
Peijia Medical Ltd.
―
LifeTech Scientific Corporation
―
AK Medical Holdings Ltd.
―
Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H
―
MicroPort NeuroTech Limited
―
Options Prices
Currently, No data available
---